Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
International Journal of Diabetes in Developing Countries
Erschienen in: International Journal of Diabetes in Developing Countries 2/2017

14.03.2015 | Original Article

Targeting inflammation using celecoxib with glimepiride in the treatment of obese type 2 diabetic Egyptian patients

verfasst von: Hoda El-Bahrawy, Sahar Hegazy, Wael Farrag, Rehab Werida

Erschienen in: International Journal of Diabetes in Developing Countries | Ausgabe 2/2017

Einloggen, um Zugang zu erhalten

Abstract

Obesity, insulin resistance (IR), inflammation, and progressive decline in pancreatic β cell function are major features of type 2 diabetes mellitus (T2DM). We aimed to investigate the effect of co-administration of celecoxib (CE) with glimepiride (GL) in the treatment of obese T2DM patients. Body Mass Index (BMI), serum glucose, C-peptide, lipid profile, adiponectin, tumor necrosis factor-α (TNF-α), visfatin, and leptin levels were determined in 40 obese T2DM patients before and after treatment with GL alone or in combination with a selective cyclooxygenase-2 (COX-2) inhibitor CE for 3 months. Homeostasis model assessment of insulin resistance (HOMA2-IR) and atherogenic index (AI) was calculated. Increased levels of serum glucose, C-peptide, total cholesterol (TCH), low-density lipoprotein (LDL-C), triglycerides (TGs), visfatin, TNF-α, leptin, AI, and HOMA2-IR shown in obese diabetic patients were significantly decreased after co-treatment with GL plus CE compared to patients who received GL alone. On the other hand, adiponectin levels showed a significant increase after treatment. The obtained results demonstrate that targeting inflammation using celecoxib with glimepiride improves insulin resistance, glycemia, and inflammatory process in obese type 2 diabetics.
Literatur
1.
Cernea S, Dobreanu M. Diabetes and beta cell function: from mechanisms to evaluation and clinical implications. Biochem Med (Zagreb). 2013;23(3):266–80.CrossRef
2.
3.
4.
Uslu S, Kebapçi N, Kara M, Bal C. Relationship between adipocytokines and cardiovascular risk factors in patients with type 2 diabetes mellitus. Exp Ther Med. 2012;4(1):113–20.PubMedPubMedCentral
5.
Raucci R, Rusolo F, Sharma A, Colonna G, Castello G, Costantini S. Functional and structural features of adipokine family. Cytokine. 2013;61(1):1–14.CrossRefPubMed
6.
Konheim YL, Wolford JK. Association of a promoter variant in the inducible cyclooxygenase-2 gene (PTGS2) with type 2 diabetes mellitus in Pima Indians. Hum Genet. 2003;113:377–81.CrossRefPubMed
7.
Helmersson J, Vessby B, Larsson A, Basu S. Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population. Circulation. 2004;109:1729–34.CrossRefPubMed
8.
Hsieh PS, Tsai HC, Kuo CH, Chan JY, Shyu JF, Cheng WT, et al. Selective COX-2 inhibition improves whole body and muscular insulin resistance in fructose-fed rats. Eur J Clin Invest. 2008;38(11):812–9.CrossRefPubMed
9.
Hsieh PS, Jin JS, Chiang CF, Chan PC, Chen CH, Shih KC. COX-2-mediated inflammation in fat is crucial for obesity-linked insulin resistance and fatty liver. Obesity (Silver Spring). 2009;17:1150–7.
10.
Alpert E, Gruzman A, Tennenbaum T, Sasson S. Selective cyclooxygenase-2 inhibitors stimulate glucose transport in L6 myotubes in a protein kinase C[delta]-dependent manner. Biochem Pharmacol. 2007;73(3):368–77.CrossRefPubMed
11.
Coll T, Palomer X, Blanco-Vacca F, Escola-Gil JC, Sanchez RM, Laguna JC, et al. Cyclooxygenase 2 inhibition exacerbates palmitate-induced inflammation and insulin resistance in skeletal muscle cells. Endocrinology. 2010;151(2):537–48.CrossRefPubMed
12.
Gokalp D, Bahceci M, Ozmen S, Arikan S, Tuzcu A, Danıs R. Adipocyte volumes and levels of adipokines in diabetes and obesity. Diabetes Metab Syndr Clin Res Rev. 2008;2:253–8.CrossRef
13.
Aubrée-Lecat A, Hervagault C, Delacour A, Beaude P, Bourdillon C, Remy MH. Direct electrochemical determination of glucose oxidase in biological samples. Anal Biochem. 1989;178(2):427–30.CrossRefPubMed
14.
Gonen G, Rubenstein AH. Haemoglobin A1 and diabetes mellitus. Diabetologia. 1978;15(1):1–8.CrossRefPubMed
15.
Kim MK. Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti- cancer agent FK-866. J Mol Biol. 2006;362(1):66–77.CrossRefPubMed
16.
Brouckaert P, Libert C, Everaerdt B, Takahashi N, Cauwels A, Fiers W. Tumor necrosis factor, its receptors and the connection with interleukin 1 and interleukin 6. Immunobiology. 1993;187(3–5):317–29.CrossRefPubMed
17.
Tsao TS, Lodish HF, Fruebis J. ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol. 2002;440(2-3):213–21.CrossRefPubMed
18.
Turkington RW, Estkowski A, Link M. Secretion of insulin or connecting peptide: a predictor of insulin dependence of obese "diabetics". Arch Intern Med. 1982;142(6):1102–5.CrossRefPubMed
19.
Wiesner G, Vaz M, Collier G, Seals D, Kaye D, Jennings G, et al. Leptin is released from the human brain: influence of adiposity and gender. J Clin Endocrinol Metab. 1999;84(7):2270–4.PubMed
20.
Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care. 2004;27(6):1487–95.CrossRefPubMed
21.
Bucolo G, David H. Quantitative determination of serum triglycerides by the use of enzymes. Clin Chem. 1973;19(5):476–82.PubMed
22.
Allian CC, Poon LS, Chan CS, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;20(4):470–5.
23.
Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.PubMed
24.
Hermans MP, Ahn SA, Rousseau MF. The atherogenic dyslipidemia ratio [log(TG)/HDL-C] is associated with residual vascular risk, beta-cell function loss and microangiopathy in type 2 diabetes females. Lipids Health Dis. 2012;11(132):1–8.
25.
Aroor A, McKarns S, Nistala R, Demarco V, Gardner M, Garcia-Touza M, et al. DPP-4 inhibitors as therapeutic modulators of immune cell function and associated cardiovascular and renal insulin resistance in obesity and diabetes. Cardiorenal Med. 2013;3(1):48–56.CrossRefPubMedPubMedCentral
26.
Wajchenberg BL. Beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007;28(2):187–218.CrossRefPubMed
27.
Tian YF, Hsia TL, Hsieh CH, Huang DW, Chen CH, Hsieh PS. The importance of cyclooxygenase 2-mediated oxidative stress in obesity-induced muscular insulin resistance in high-fat-fed rats. Life Sci. 2011;89(3–4):107–14.CrossRefPubMed
28.
Liu TT, Shih KC, Kao CC, Cheng WT, Hsieh PS. Importance of cyclooxygenase 2-mediated low-grade inflammation in the development of fructose-induced insulin resistance in rats. Chin J Physiol. 2009;52(2):65–71.CrossRefPubMed
29.
Sone H, Takahashi A, Yamada N. Ibuprofen-related hypoglycemia in a patient receiving sulfonylurea. Ann Intern Med. 2001;134:344.CrossRefPubMed
30.
31.
Matsuda M, Shimomura I. Roles of adiponectin and oxidative stress in obesity-associated metabolic and cardiovascular diseases. Rev Endocr Metab Disord. 2014;15(1):1–10.CrossRefPubMed
32.
33.
Jacob S, Machann J, Rett K, Brechtel K, Volk A, Renn W, et al. Association of increased intramyocellular lipid content with insulin resistance in lean nondiabetic offspring of type 2 diabetic subjects. Diabetes. 1999;48(5):1113–9.CrossRefPubMed
34.
Jeusette IC, Lhoest ET, Istasse LP, Diez MO. Influence of obesity on plasma lipid and lipoprotein concentrations in dogs. Am J Vet Res. 2005;66(1):81–6.CrossRefPubMed
Metadaten
Titel
Targeting inflammation using celecoxib with glimepiride in the treatment of obese type 2 diabetic Egyptian patients
verfasst von
Hoda El-Bahrawy
Sahar Hegazy
Wael Farrag
Rehab Werida
Publikationsdatum
14.03.2015
Verlag
Springer India
Erschienen in
International Journal of Diabetes in Developing Countries / Ausgabe 2/2017
Print ISSN: 0973-3930
Elektronische ISSN: 1998-3832
DOI
https://doi.org/10.1007/s13410-015-0355-7

Weitere Artikel der Ausgabe 2/2017

International Journal of Diabetes in Developing Countries 2/2017 Zur Ausgabe

Original Article

Does white blood cell count predict diabetes incidence in the general Chinese population over time?

Original Article

A CT-based comparative study of radiological patterns of pulmonary tuberculosis in patients with type 2 diabetes versus non-diabetics

Original Article

Diabetes foot complication: assessing primary and secondary outcomes of multidisciplinary team versus standard care (a systematic review)

Original Article

Lipid peroxidation, antioxidants, lipid profile, and HbA1c in diabetic patients

Original Article

Prevalence of the metabolic syndrome in the middle-aged and older Chinese population

Original Article

Importance of anthropometry in assessing insulin resistance as a pre-alarming sign before the onset of metabolic syndrome: a study among apparently healthy subjects